FULL DISCLOSURE: Canacom Group is long the equity of Cardiol Therapeutics.
In this conversation with David Elsley, President and CEO of Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL), we discuss the company’s progress in inflammatory heart disease, including momentum in the Phase 3 MAVERIC trial for recurrent pericarditis, new data from the Phase 2 ARCHER program in myocarditis, and why the latest results could have implications far beyond rare disease.
David explains what makes these conditions so difficult to treat, why the current standard of care remains limited, and how Cardiol is positioning both its lead oral therapy and its next-stage once-monthly heart failure asset for major value-creating milestones ahead.
What makes this discussion stand out is that it is not just about one trial update. David lays out how the company is moving from treating a rare cardiac disease towards much larger commercial opportunities, why the recent myocarditis data matters scientifically, and how Cardiol’s balance sheet now supports key catalysts through Phase 3 readout, regulatory work, and the advance of CRD38 into clinical development.
FULL DISCLOSURE: Canacom Group, the parent company of The Deep Dive is long the equity of Cardiol Therapeutics. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
